Pfizer to Buy Metsera for $4.9 Billion in Obesity Drug Bet

Core Insights - Pfizer Inc. is acquiring obesity startup Metsera Inc. for $4.9 billion to enhance its competitive position against rival drugmakers in the weight-loss medication market [1] - The acquisition price is set at $47.50 in cash per share, with additional contingent payments of up to $22.50 per share based on the achievement of specific regulatory milestones, bringing the total potential value of the deal to $7.3 billion [1] - The deal includes a 43% premium over Metsera's closing share price on the previous Friday, indicating a strong valuation for the acquisition [1]